Walnut Creek, CALIFORNIA2 Active Studies

Pulmonary Embolism Clinical Trials in Walnut Creek, CALIFORNIA

Find 2 actively recruiting pulmonary embolism clinical trials in Walnut Creek, CALIFORNIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
288
Enrolling

Recruiting Pulmonary Embolism Studies in Walnut Creek

About Pulmonary Embolism Clinical Trials in Walnut Creek

Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.

There are currently 2 pulmonary embolism clinical trials recruiting participants in Walnut Creek, CALIFORNIA. These studies are seeking a combined 288 participants. Research is being sponsored by Zealand Pharma, COUR Pharmaceutical Development Company, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Embolism Clinical Trials in Walnut Creek — FAQ

Are there pulmonary embolism clinical trials in Walnut Creek?

Yes, there are 2 pulmonary embolism clinical trials currently recruiting in Walnut Creek, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Walnut Creek?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Walnut Creek research site will contact you about next steps.

Are clinical trials in Walnut Creek free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Walnut Creek studies also compensate for your time and travel.

What pulmonary embolism treatments are being tested?

The 2 active trials in Walnut Creek are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.

Data updated March 2, 2026 from ClinicalTrials.gov